A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Penciclovir (Denavir)

Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor class · 4 generic manufacturers · 4 ANDAs filed at FDA.

First FDA approval2018-09-24
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$5.5M in CY2024 Part D spend9K claims · 6K beneficiaries · 329 plans surveyed

Lowest NADAC
$64.73/unit
5 NDCs benchmarked, lowest of all strengths.
Average NADAC
$82.71
Across all dosage forms in distribution.
Highest NADAC
$154.62
Range is tight.
Plans with PA
2 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Penciclovir used for?

Penciclovir is a Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Penciclovir?

Yes. 4 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Penciclovir?

Across 329 Part D plans, Penciclovir averages $82.71/unit (NADAC). Lowest available: $64.73/unit. Highest in distribution: $154.62/unit.

Is Penciclovir on the FDA shortage list?

No. Penciclovir is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor1 alternative in D1
01
Valacyclovir
Brand: VALTREX
$0.230Lowest NADAC
9Generic mfrs
$171.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (5 approvals on file) · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.